Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Palisade Bio Doses The First Patients In Its Phase 1b Study Of PALI-2108, A First-In-Class Ileocolonic-Targeted PDE4 Inhibitor Prodrug For Fibrostenotic Crohn's Disease—A Condition With No Approved Therapies

Author: Benzinga Newsdesk | October 20, 2025 08:48am

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies

Topline safety, PK, and PD data anticipated in Q1 2026

Advances ongoing development of PALI-2108 across fibrostenotic Crohn's disease and ulcerative colitis, with Phase 2 IND submission planned for H1 2026

 Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing precision therapies for autoimmune, inflammatory, and fibrotic diseases, today announced that the first patients have been dosed in its Phase 1b clinical study evaluating PALI-2108, a first-in-class, ileocolonic-targeted PDE4 inhibitor prodrug, for the treatment of fibrostenotic Crohn's disease (FSCD). Topline data are anticipated in the first quarter of 2026.

"The initiation of patient dosing marks a significant milestone in our mission to address fibrostenotic complications in Crohn's disease, an area with no current approved medical therapies," said Dr. Mitchell Jones, Chief Medical Officer of Palisade Bio. "This mechanistic study is designed to generate critical insights into how PALI-2108 modulates inflammatory and fibrotic pathways in intestinal tissue. Together with data from our ulcerative colitis studies, these findings will inform our planned Phase 2 development and regulatory interactions in 2026."

The open-label, exploratory Phase 1b study will enroll approximately 6 to 12 patients with FSCD. The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of once-daily oral dosing of PALI-2108 over a 14-day treatment period. PALI-2108 is a next-generation phosphodiesterase-4 (PDE4) inhibitor prodrug engineered for targeted activation in the terminal ileum and colon, designed to provide high local tissue exposure with minimal systemic absorption.

In addition to safety and PK/PD assessments, the study will evaluate tissue-level pharmacology and molecular responses using paired ileal biopsies and peripheral blood mononuclear cells (PBMCs). Analyses will include single-nucleus and single-cell RNA sequencing to characterize treatment-induced changes in inflammatory and fibrotic signaling. Exploratory endpoints include endoscopic, histologic, and intestinal ultrasound (IUS) measures to assess structural and inflammatory features of FSCD lesions.

Data from this study, together with results from the Phase 1a/1b ulcerative colitis (UC) program, are expected to support Phase 2 Investigational New Drug (IND) submissions to the U.S. Food and Drug Administration (FDA) in the first half of 2026.


 

Posted In: PALI

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist